{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:30:16Z","timestamp":1793219416630,"version":"4.5.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Despite growing evidence supporting the efficacy and safety of the MiniMed\u2122 780G recommended settings (Glucose Target 100 mg\/dL and Active Insulin Time 2 hours), their adoption in routine practice remains limited, mainly due to concerns about hypoglycemia. This study aimed to evaluate the impact of switching to these settings in pediatric and young patients with type 1 diabetes (T1D).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective longitudinal analysis in children and young adults using MiniMed\u2122780G system at our center. Patients who switched from their initial settings to a glucose target of 100 mg\/dL and an active insulin time of 2 hours for clinical indications were included. Data were retrospectively collected 3 months after switch. Glycemic metrics were compared over the 14 days before the switch (T0) and at 1 month (T1), and 3 months (T3).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ninety-one patients with a mean age of 17.89y were included, 81.3% of whom already had a glucose target of 100 mg\/dL at baseline. Therefore, in most cases the primary change was reducing AIT from 3 to 2 hours. After switching to the recommended settings, Time in Range (TIR) significantly increased (p&amp;lt;0.001) at T1 (71.9%\n                      <jats:italic>vs<\/jats:italic>\n                      74.8%) and T3 (71.9%\n                      <jats:italic>vs<\/jats:italic>\n                      75.0%). Time in target range (TITR) similarly improved from 47.2% at T0 to 51.4% at T1 and 50.9% at T3 (p&amp;lt;0.001) without any significant increase in time below range (TBR). The proportion of patients meeting all ADA-recommended glycemic targets rose from 29.5% at baseline to 40% at T3. Following the switch, the contribution of automatic correction boluses to the total insulin dose increased, while overall daily insulin requirements remained stable.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Switching to the recommended MiniMed\u2122780G settings, driven primarily by AIT reduction in most patients, was safe and effective, improving glycemic control without increasing hypoglycemia. These findings support broader use of these settings in pediatric and young adult patient with type 1 diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1670266","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T04:15:11Z","timestamp":1757650511000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-world efficacy of MiniMed\u2122780G recommended settings (glycemic target 100 mg\/dL, active insulin time 2 hours) in youth and young adults with type 1 diabetes"],"prefix":"10.3389","volume":"16","author":[{"given":"Marta","family":"Bassi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giordano","family":"Spacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Pezzotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Di Jorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Siri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pintabona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Calevo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Minuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Maghnie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2338922","DOI":"10.1155\/2024\/2338922","article-title":"Trends in the incidence of type 1 diabetes in European children and adolescents from 1994 to 2022: A systematic review and meta-analysis","volume":"2024","author":"Ruiz-Grao","year":"2024","journal-title":"Pediatr Diabetes"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05648-4","article-title":"Effectiveness of continuous glucose monitoring in maintaining glycaemic control among people with type 1 diabetes mellitus: a systematic review of randomised controlled trials and meta-analysis","volume":"65","author":"Teo","year":"2022","journal-title":"Diabetologia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.endien.2024.11.010","article-title":"Automated insulin delivery systems in the treatment of diabetes: Benefits, challenges, and practical considerations in pediatric patients","volume":"71","author":"Enes Romero","year":"2024","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15718","article-title":"Real-world glycaemic outcomes of automated insulin delivery in type 1 diabetes: A meta-analysis","volume":"26","author":"Yang","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1177\/19322968241248404","article-title":"Automated insulin delivery systems in pediatric type 1 diabetes: A narrative review","volume":"18","author":"Adolfsson","year":"2024","journal-title":"J Diabetes Sci Technol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1089\/dia.2023.0446","article-title":"A peek under the hood: explaining the miniMed\u2122 780G algorithm with meal detection technology","volume":"26","author":"Grosman","year":"2024","journal-title":"Diabetes Technol Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/life13030783","article-title":"Automated insulin delivery (AID) systems: use and efficacy in children and adults with type 1 diabetes and other forms of diabetes in europe in early 2023","volume":"13","author":"Bassi","year":"2023","journal-title":"Life (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2023.0433","article-title":"Celebrating the data from 100,000 real-world users of the miniMed\u2122 780G system in Europe, Middle East, and Africa collected over 3 years: from data to clinical evidence","volume":"26","author":"Choudhary","year":"2024","journal-title":"Diabetes Technol Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1159\/000543266","article-title":"International society for pediatric and adolescent diabetes clinical practice consensus guidelines 2024: glycemic targets","volume":"97","author":"de Bock","year":"2024","journal-title":"Horm Res Paediatr"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-1581","article-title":"Time in tight glucose range in type 1 diabetes: predictive factors and achievable targets in real-world users of the miniMed 780G system","volume":"47","author":"Castan\u00f1eda","year":"2024","journal-title":"Diabetes Care"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2250","article-title":"Improved glycemic outcomes with medtronic miniMed advanced hybrid closed-loop delivery: results from a randomized crossover trial comparing automated insulin delivery with predictive low glucose suspend in people with type 1 diabetes","volume":"44","author":"Collyns","year":"2021","journal-title":"Diabetes Care"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2021.0203","article-title":"Real-world performance of the miniMed\u2122 780G system: first report of outcomes from 4120 users","volume":"24","author":"Silva","year":"2022","journal-title":"Diabetes Technol Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14714","article-title":"Comparison of MiniMed 780G system performance in users aged younger and older than 15\u2009years: Evidence from 12\u2009870 real-world users","volume":"24","author":"Arrieta","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16226","article-title":"Long-term use of Minimed\u2122 780G in children and adolescents with type 1 diabetes under real-world conditions: The benefits of optimal settings","volume":"27","author":"Bombaci","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1089\/dia.2023.0453","article-title":"Early real-world performance of the miniMed\u2122 780G advanced hybrid closed-loop system and recommended settings use in the United States","volume":"26","author":"Thrasher","year":"2024","journal-title":"Diabetes Technol Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"111832","DOI":"10.1016\/j.diabres.2024.111832","article-title":"Excellence in the management of Advanced Hybrid Closed-Loop Systems: Lessons from the Polish cohort","volume":"216","author":"Matejko","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S006","article-title":"6. Glycemic goals and hypoglycemia: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14807","article-title":"Predictors of time in target glucose range in real-world users of the MiniMed 780G system","volume":"24","author":"Castan\u00f1eda","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2021.0319","article-title":"Safety and glycemic outcomes during the miniMed\u2122 Advanced hybrid closed-loop system pivotal trial in adolescents and adults with type 1 diabetes","volume":"24","author":"Carlson","year":"2022","journal-title":"Diabetes Technol Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1670266\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T04:15:12Z","timestamp":1757650512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1670266\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":20,"alternative-id":["10.3389\/fendo.2025.1670266"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1670266","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"article-number":"1670266"}}